Cellular therapies in rheumatic and musculoskeletal diseases

A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus...

Full description

Saved in:
Bibliographic Details
Main Authors: Pedro Franco-Fuquen, Juana Figueroa-Aguirre, David A. Martínez, Eider F. Moreno-Cortes, Juan E. Garcia-Robledo, Fabio Vargas-Cely, Daniela A. Castro-Martínez, Mustafa Almaini, Januario E. Castro
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Journal of Translational Autoimmunity
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589909024000340
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832583107152183296
author Pedro Franco-Fuquen
Juana Figueroa-Aguirre
David A. Martínez
Eider F. Moreno-Cortes
Juan E. Garcia-Robledo
Fabio Vargas-Cely
Daniela A. Castro-Martínez
Mustafa Almaini
Januario E. Castro
author_facet Pedro Franco-Fuquen
Juana Figueroa-Aguirre
David A. Martínez
Eider F. Moreno-Cortes
Juan E. Garcia-Robledo
Fabio Vargas-Cely
Daniela A. Castro-Martínez
Mustafa Almaini
Januario E. Castro
author_sort Pedro Franco-Fuquen
collection DOAJ
description A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. The persistence of these autoreactive B cells within lymphatic organs and inflamed tissues impairs the effectiveness of B-cell-depleting monoclonal antibodies like rituximab.A promising therapeutic approach involves using T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens. This strategy has demonstrated efficacy in treating B-cell malignancies by achieving long-term depletion of malignant and normal B cells. Preliminary data from patients with RMDs, particularly those with lupus erythematosus and dermatomyositis, suggest that CAR T-cells targeting CD19 can induce rapid and sustained depletion of circulating B cells, leading to complete clinical and serological responses in cases that were previously unresponsive to conventional therapies.This review will provide an overview of the current state of preclinical and clinical studies on the use of CAR T-cells and other cellular therapies for RMDs. Additionally, it will explore potential future applications of these innovative treatment modalities for managing patients with refractory and recurrent manifestations of these diseases.
format Article
id doaj-art-9c73e22170f84f70bda3258a2354c871
institution Kabale University
issn 2589-9090
language English
publishDate 2025-06-01
publisher Elsevier
record_format Article
series Journal of Translational Autoimmunity
spelling doaj-art-9c73e22170f84f70bda3258a2354c8712025-01-29T05:01:39ZengElsevierJournal of Translational Autoimmunity2589-90902025-06-0110100264Cellular therapies in rheumatic and musculoskeletal diseasesPedro Franco-Fuquen0Juana Figueroa-Aguirre1David A. Martínez2Eider F. Moreno-Cortes3Juan E. Garcia-Robledo4Fabio Vargas-Cely5Daniela A. Castro-Martínez6Mustafa Almaini7Januario E. Castro8Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USA; Corresponding author. 6161 E Mayo Blvd, Phoenix, AZ, 85014, USA.Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USADivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USAStanford University, Stanford, CA, USARheumatology, Allergy & Clinical Immunology Division, Mafraq Hospital, United Arab EmiratesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA; Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, USA; Corresponding author. 6161 E Mayo Blvd, Phoenix, AZ, 85014, USA.A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. The persistence of these autoreactive B cells within lymphatic organs and inflamed tissues impairs the effectiveness of B-cell-depleting monoclonal antibodies like rituximab.A promising therapeutic approach involves using T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens. This strategy has demonstrated efficacy in treating B-cell malignancies by achieving long-term depletion of malignant and normal B cells. Preliminary data from patients with RMDs, particularly those with lupus erythematosus and dermatomyositis, suggest that CAR T-cells targeting CD19 can induce rapid and sustained depletion of circulating B cells, leading to complete clinical and serological responses in cases that were previously unresponsive to conventional therapies.This review will provide an overview of the current state of preclinical and clinical studies on the use of CAR T-cells and other cellular therapies for RMDs. Additionally, it will explore potential future applications of these innovative treatment modalities for managing patients with refractory and recurrent manifestations of these diseases.http://www.sciencedirect.com/science/article/pii/S2589909024000340Adoptive immunotherapyChimeric antigen receptorCell- and tissue-based therapyAutoimmune diseaseRheumatic and musculoskeletal disease
spellingShingle Pedro Franco-Fuquen
Juana Figueroa-Aguirre
David A. Martínez
Eider F. Moreno-Cortes
Juan E. Garcia-Robledo
Fabio Vargas-Cely
Daniela A. Castro-Martínez
Mustafa Almaini
Januario E. Castro
Cellular therapies in rheumatic and musculoskeletal diseases
Journal of Translational Autoimmunity
Adoptive immunotherapy
Chimeric antigen receptor
Cell- and tissue-based therapy
Autoimmune disease
Rheumatic and musculoskeletal disease
title Cellular therapies in rheumatic and musculoskeletal diseases
title_full Cellular therapies in rheumatic and musculoskeletal diseases
title_fullStr Cellular therapies in rheumatic and musculoskeletal diseases
title_full_unstemmed Cellular therapies in rheumatic and musculoskeletal diseases
title_short Cellular therapies in rheumatic and musculoskeletal diseases
title_sort cellular therapies in rheumatic and musculoskeletal diseases
topic Adoptive immunotherapy
Chimeric antigen receptor
Cell- and tissue-based therapy
Autoimmune disease
Rheumatic and musculoskeletal disease
url http://www.sciencedirect.com/science/article/pii/S2589909024000340
work_keys_str_mv AT pedrofrancofuquen cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT juanafigueroaaguirre cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT davidamartinez cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT eiderfmorenocortes cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT juanegarciarobledo cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT fabiovargascely cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT danielaacastromartinez cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT mustafaalmaini cellulartherapiesinrheumaticandmusculoskeletaldiseases
AT januarioecastro cellulartherapiesinrheumaticandmusculoskeletaldiseases